Literature DB >> 18725592

Second consensus statement on the diagnosis of multiple system atrophy.

S Gilman1, G K Wenning, P A Low, D J Brooks, C J Mathias, J Q Trojanowski, N W Wood, C Colosimo, A Dürr, C J Fowler, H Kaufmann, T Klockgether, A Lees, W Poewe, N Quinn, T Revesz, D Robertson, P Sandroni, K Seppi, M Vidailhet.   

Abstract

BACKGROUND: A consensus conference on multiple system atrophy (MSA) in 1998 established criteria for diagnosis that have been accepted widely. Since then, clinical, laboratory, neuropathologic, and imaging studies have advanced the field, requiring a fresh evaluation of diagnostic criteria. We held a second consensus conference in 2007 and present the results here.
METHODS: Experts in the clinical, neuropathologic, and imaging aspects of MSA were invited to participate in a 2-day consensus conference. Participants were divided into five groups, consisting of specialists in the parkinsonian, cerebellar, autonomic, neuropathologic, and imaging aspects of the disorder. Each group independently wrote diagnostic criteria for its area of expertise in advance of the meeting. These criteria were discussed and reconciled during the meeting using consensus methodology.
RESULTS: The new criteria retain the diagnostic categories of MSA with predominant parkinsonism and MSA with predominant cerebellar ataxia to designate the predominant motor features and also retain the designations of definite, probable, and possible MSA. Definite MSA requires neuropathologic demonstration of CNS alpha-synuclein-positive glial cytoplasmic inclusions with neurodegenerative changes in striatonigral or olivopontocerebellar structures. Probable MSA requires a sporadic, progressive adult-onset disorder including rigorously defined autonomic failure and poorly levodopa-responsive parkinsonism or cerebellar ataxia. Possible MSA requires a sporadic, progressive adult-onset disease including parkinsonism or cerebellar ataxia and at least one feature suggesting autonomic dysfunction plus one other feature that may be a clinical or a neuroimaging abnormality.
CONCLUSIONS: These new criteria have simplified the previous criteria, have incorporated current knowledge, and are expected to enhance future assessments of the disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18725592      PMCID: PMC2676993          DOI: 10.1212/01.wnl.0000324625.00404.15

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  37 in total

1.  Clinical diagnosis of multiple system atrophy: level of agreement between Quinn's criteria and the consensus conference guidelines.

Authors:  C Colosimo; N Vanacore; V Bonifati; G Fabbrini; A Rum; G De Michele; M De Mari; U Bonuccelli; D J Nicholl; G Meco
Journal:  Acta Neurol Scand       Date:  2001-04       Impact factor: 3.209

2.  The dopaminergic response in multiple system atrophy.

Authors:  A J Hughes; C Colosimo; B Kleedorfer; S E Daniel; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-11       Impact factor: 10.154

3.  Frequency of orthostatic hypotension in a community based cohort of patients with Parkinson's disease.

Authors:  L M Allcock; K Ullyart; R A Kenny; D J Burn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-10       Impact factor: 10.154

Review 4.  Multiple system atrophy--the nature of the beast.

Authors:  N Quinn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

5.  Reduced genital sensitivity in female patients with multiple system atrophy of parkinsonian type.

Authors:  Wolfgang H Oertel; Tobias Wächter; Niall P Quinn; Gudrun Ulm; Dirk Brandstädter
Journal:  Mov Disord       Date:  2003-04       Impact factor: 10.338

6.  Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome).

Authors:  M I Papp; J E Kahn; P L Lantos
Journal:  J Neurol Sci       Date:  1989-12       Impact factor: 3.181

7.  PET measurement of cardiac and nigrostriatal denervation in Parkinsonian syndromes.

Authors:  David M Raffel; Robert A Koeppe; Roderick Little; Chia-Ning Wang; Suyu Liu; Larry Junck; Mary Heumann; Sid Gilman
Journal:  J Nucl Med       Date:  2006-11       Impact factor: 10.057

8.  Erectile and urinary dysfunction may be the presenting features in patients with multiple system atrophy: a retrospective study.

Authors:  K Kirchhof; A N Apostolidis; C J Mathias; C J Fowler
Journal:  Int J Impot Res       Date:  2003-08       Impact factor: 2.896

9.  Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease.

Authors:  Frédéric Courbon; Christine Brefel-Courbon; Claire Thalamas; Marie-Jeanne Alibelli; Isabelle Berry; Jean-Louis Montastruc; Olivier Rascol; Jean-Michel Senard
Journal:  Mov Disord       Date:  2003-08       Impact factor: 10.338

10.  Autonomic involvement in extrapyramidal and cerebellar disorders.

Authors:  P Sandroni; J E Ahlskog; R D Fealey; P A Low
Journal:  Clin Auton Res       Date:  1991-06       Impact factor: 4.435

View more
  899 in total

1.  Subclinical nigrostriatal dopaminergic denervation in the cerebellar subtype of multiple system atrophy (MSA-C).

Authors:  Esteban Muñoz; Alex Iranzo; Sebastian Rauek; Francisco Lomeña; Judith Gallego; Doménec Ros; Joan Santamaría; Eduardo Tolosa
Journal:  J Neurol       Date:  2011-06-03       Impact factor: 4.849

2.  Myeloperoxidase inhibition ameliorates multiple system atrophy-like degeneration in a transgenic mouse model.

Authors:  Nadia Stefanova; Biljana Georgievska; Håkan Eriksson; Werner Poewe; Gregor K Wenning
Journal:  Neurotox Res       Date:  2011-12-08       Impact factor: 3.911

Review 3.  Multiple system atrophy: a clinical and neuropathological perspective.

Authors:  Kiren Ubhi; Phillip Low; Eliezer Masliah
Journal:  Trends Neurosci       Date:  2011-09-29       Impact factor: 13.837

4.  Differential involvement of the periaqueductal gray in multiple system atrophy.

Authors:  Eduardo E Benarroch; Ann M Schmeichel; Phillip A Low; Joseph E Parisi
Journal:  Auton Neurosci       Date:  2010-08-21       Impact factor: 3.145

5.  Accuracy of death certificates for recording parkinsonian syndromes and associated dementia.

Authors:  Hanxu Shi; Carl Counsell
Journal:  J Neurol       Date:  2020-07-31       Impact factor: 4.849

Review 6.  Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Pharmacol Ther       Date:  2013-02-04       Impact factor: 12.310

7.  Different loss of dopamine transporter according to subtype of multiple system atrophy.

Authors:  Hae Won Kim; Jae Seung Kim; Minyoung Oh; Jungsu S Oh; Sang Joo Lee; Seung Jun Oh; Sun Ju Chung; Chong Sik Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-09-19       Impact factor: 9.236

Review 8.  Combination therapies: The next logical Step for the treatment of synucleinopathies?

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Mov Disord       Date:  2015-09-21       Impact factor: 10.338

Review 9.  The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases.

Authors:  Filippo Baldacci; Sonia Mazzucchi; Alessandra Della Vecchia; Linda Giampietri; Nicola Giannini; Maya Koronyo-Hamaoui; Roberto Ceravolo; Gabriele Siciliano; Ubaldo Bonuccelli; Fanny M Elahi; Andrea Vergallo; Simone Lista; Filippo Sean Giorgi; Harald Hampel
Journal:  Expert Rev Mol Diagn       Date:  2020-02-27       Impact factor: 5.225

Review 10.  Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases.

Authors:  Nathan P Staff; David T Jones; Wolfgang Singer
Journal:  Mayo Clin Proc       Date:  2019-05       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.